The Plot Twist Nobody Expected
Here's something that caught my attention: what if the secret to beating colon cancer wasn't doing surgery first, then chemo? What if we've been doing it backwards this whole time?
A recent clinical trial is suggesting exactly that. Instead of the traditional approach—surgery followed by months of chemotherapy—researchers tried giving patients immunotherapy upfront, before they even went under the knife. And the results? They're honestly pretty stunning.
When "Almost Three Years" Means Something Really Important
Let me break down why this matters so much. In a normal colon cancer treatment scenario, about one in four patients sees their cancer come back within three years. That's a sobering statistic, and it drives a lot of anxiety even after treatment.
But in this trial? Out of the 32 patients studied, none—and I mean zero—have experienced a relapse after nearly three years of follow-up. Even patients who still had tiny traces of cancer remaining after the initial immunotherapy showed no growth or spread whatsoever.
That's the kind of "nothing happened" that doctors absolutely love to see.
The Nine-Week Game Changer
The treatment itself is pretty straightforward: nine weeks of a drug called pembrolizumab before surgery. That's it. No months of chemo afterward. No prolonged side effects beating up the body.
Now, I'll be honest—this trial was specifically designed for a particular type of colon cancer (the kind that's MMR deficient or MSI-high). This accounts for roughly 2,000 to 3,000 new cases yearly in the UK. So it's not a universal cure, and the researchers are clear about that.
But for those patients who do have this genetic subtype? This could be genuinely life-changing.
Here's Where It Gets Really Cool: Blood Tests
One of my favorite parts of this research is how they figured out why the treatment worked so well. The team developed personalized blood tests that can detect cancer DNA floating around in the bloodstream.
Think about this: before someone ever develops symptoms of recurrence, a simple blood test could potentially tell doctors, "Hey, this treatment worked perfectly—you're good to go," or conversely, "We need to be more aggressive here."
That kind of personalized medicine is the direction healthcare should be moving, and it's genuinely exciting to see it actually happening in practice.
The Bigger Picture on Colon Cancer
Colon cancer is the fourth most common cancer in the UK, with about 44,000 new cases every year. What's particularly concerning is that cases among younger people have been steadily climbing. It's not just a disease affecting retirees anymore.
The survival rates vary dramatically depending on when cancer is caught—90% for early stage one, but only 10% for stage four. So finding better treatments that work earlier in the disease process is genuinely important.
Why This Feels Different
What strikes me about this research is the shift in thinking. Instead of viewing immunotherapy as a backup plan (something you use when standard treatments fail), researchers are asking: "What if this is the better first move?"
That's a fundamental rethinking of treatment strategy, and it's exactly the kind of question that drives real progress in medicine.
The team from UCL and UCLH worked with multiple hospitals across the UK to gather this data, and they're being appropriately cautious about what it means. This isn't a cure-all announcement. It's a "we found something really promising in this specific patient population" announcement.
Which, honestly? That's way more credible and encouraging than hype.
What Happens Next?
Larger trials will obviously need to happen. The results need to be replicated. Scientists need to figure out if this approach works for other types of colon cancer beyond just the MSI-high subtype.
But for now, this is exactly the kind of incremental, methodical progress that actually leads to better outcomes in the real world. And that's worth paying attention to.
If you or someone you know is dealing with colon cancer, these are definitely conversations worth having with your medical team. The landscape of what's possible is shifting—and that's genuinely good news.